Peaches Biotech receives financial approval from the Ministry of Science and Innovation for two of its advanced therapy projects
- The State Research Agency (AEI) of the Ministry of Science and Innovation approves financing for two Peaches Biotech projects in its call for public-private collaboration
- The chosen investigations are based on the development of a cell therapy against pancreatic cancer and tumor labeling with immunotoxins.
Madrid, November 29, 2022.- The Spanish biotech group Peaches Biotech, a company specialized in advanced therapies, take a qualitative leap in the Spanish Science and Technology ecosystem, having managed to surpass the scientific-technological evaluation of the State Agency for Investigation (AEI) in its last call for public-private collaboration for two of its projects. The already mentioned call is characterized, like all those of the AEI, by the demanding selection methodology that entails that only a small percentage of projects are approved.
In this line of matter, the Spanish Group will obtain public financial support, specifically non-refundable grants, which are difficult to obtain for small technology companies. This represents a significant economic injection as well as support for its research work to provide the patient and the market, innovative medicines based on advanced therapies.
The two approved projects by the AEI are:
- "Development of a research product for adoptive cell therapy opTcells for patients with gastrointestinal cancer", where the Peaches group leads a consortium in which companies from the group itself and public centers collaborate, such as the Health Research Institute of Hospital 12 de October. In this project, the overall objective is to generate autologous T cells from peripheral blood, to combat the patient's own gastrointestinal tumor.
- "Tumor marking with immunotoxins based on Granulysin". In this case, the participating companies of the Peaches Biotech group collaborate with the University of Zaragoza. The objective is to carry out a phase I clinical trial in cancer patients, selected by systemic injection of immunotoxins, which have already been successful in preclinical trials and have shown that recombinant Granulysin is an effective antitumor treatment.
In the words of the company's CEO, Juan Carlos de Gregorio: “¨For Peaches Biotech, a company that mainly invests its own resources for the development of its R+D+I, receiving funding from the AEI represents an important boost. and reaffirms the company's strategy that is committed to collaborating with prestigious public research centers. In fact, the two approved projects are based on patent licenses that emanate from this collaboration, one of them with the University of Zaragoza and the other with Harvard Medical School. And it is especially relevant because all our projects are aimed at combating pathologies of high prevalence and high impact for the National Health System”.
The recognition from the Ministry of Science and Innovation places Peaches Biotech in the group of most promising Spanish technology companies that work to bring innovative medicines based on advanced therapies to the patient and to the market.